Skip to main content
All lobbying filings

FEROX STRATEGIES

FEROX STRATEGIES filed a Q1 report for ASSOCIATION FOR ACCESSIBLE MEDICINES on April 17, 2026, reporting $40,000 in lobbying income.

Lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES · Trade association for generics and biosimilar manufacturers.

All filings by FEROX STRATEGIES · Everything ASSOCIATION FOR ACCESSIBLE MEDICINES has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Income
$40,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • MARK WILLIAMS New on this filing
    Previously held: Chief of Staff, Rep. Michael Conaway // Chief of Staff, Rep. Todd Rokita // Dep. Chief of Staff/Leg. Director, Rep. Sam Johnson.
  • DEBRA DIXON New on this filing
    Previously held: Chief of staff to Rep. Xavier Becerra, legislative director to Rep. Becerra, legislative counsel to Rep. Becerra, chief of staff, Office of Policy and Planning, U.S. Department of Education, Immigration Counsel, U.S. Department of Justice
  • MICHAEL TAGGART New on this filing
    Previously held: Energy and Commerce Committee --Policy Director; Rep. Cathy McMorris Rodgers -- Legislative Director; Rep. Leonard Lance-- Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Copyright/Patent/Trademark

General issues related to patents and access to generics/biosimilars.

Health Issues

General issues related to treatment access.

Pharmacy

General issues related to generic development and commercialization.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem